APP and Alzheimer disease: Fitting with our own previous work, the most marked effect was observed with the AD model of treatment with Aβ1–42 peptide, which resulted in a decrease in esAPP (Fig. 4b), contrasted by an increase in intracellular APP (Fig. 4c).